Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System San Francisco, CA -- July 12...
Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System San Francisco, CA -- June 29, 2022...
Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development...
Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development San Francisco, CA -- May 9, 2022...
Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer San Francisco, CA -- April 13, 2022 -- InvestorsHub NewsWire -- Oncology Pharma...
SAN FRANCISCO, CA -- March 2, 2022 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK: ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to announce progress with its investment...
SAN FRANCISCO, CA -- February 23, 2022 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK: ONPH) - Oncology Pharma, Inc. ("The Company") looks toward releasing further results of the...
SAN FRANCISCO, CA -- February 17, 2022 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") wants to expand on a...
San Francisco, CA -- February 14, 2022 -- InvestorsHub NewsWire -- Oncology Pharma, Inc. ("The Company") (OTC PINK:ONPH) and Regen BioPharma, Inc. (OTC PINK:RGBP) and (OTC...
SAN FRANCISCO, CA – February 8, 2022 – InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK: ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to announce that...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.0001 | 0.001 | 0.0001 | 24818 | 0.00011665 | CS |
| 4 | 0 | 0 | 0.0001 | 0.001 | 0.0001 | 16329 | 0.00011423 | CS |
| 12 | -0.0001 | -50 | 0.0002 | 0.03 | 1.0E-6 | 9241 | 7.908E-5 | CS |
| 26 | 9.9E-5 | 9900 | 1.0E-6 | 0.12505 | 1.0E-6 | 9185 | 0.00029584 | CS |
| 52 | -0.0002 | -66.6666666667 | 0.0003 | 0.1789 | 1.0E-6 | 6643 | 0.00024902 | CS |
| 156 | -4.4199 | -99.9977375566 | 4.42 | 7.23 | 1.0E-6 | 53710 | 1.75295276 | CS |
| 260 | -0.0309 | -99.6774193548 | 0.031 | 50 | 1.0E-6 | 135424 | 6.36280218 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
